-
1897
History
Marcel Mérieux, a student of Louis Pasteur (Institut Pasteur), establishes Laboratory Marcel Mérieux in Lyon, France, specialising in microbiology.
-
1937
History
Dr. Charles Mérieux takes over his father’s laboratory.
-
1947
History
Charles Mérieux creates the French Institute of Foot-and-mouth Disease amongst the Lyonnaise abattoirs and then the Mérieux Institute.
-
1982
History
A department of Medically Assisted Procreation (MAP), focusing on couple’s infertility is integrated into Laboratory Marcel Mérieux.
-
1990
Technology
First application of the Polymerase Chain Reaction (PCR) technique, discovered at the end of the 80s, for infectious diseases (Virus, bacteria, parasite screening).
-
1993
Technology
Development of PCR technique for application in molecular biology.
-
1996
History
Laboratory Marcel Mérieux acquires the department of specialised pathology from the Institut Pasteur of Lyon
-
1998
Technology
Certification for the screening of Trisomy 21
-
1999
History
Laboratory Marcel Mérieux acquires a well-known specialised pathology lab in Ireland, Claymon Laboratories
-
2000
History
Laboratory Marcel Mérieux acquires Laboratory LCL (Claude Levy), pioneer of radio-immunology in France
-
2004
Technology
Creation of the Genetic Fingerprinting Laboratory whose mission is to establish genetic profiles for the French Justice System.
-
2008
History
Merger of Laboratory Marcel Merieux and Laboratory Claude Levy to form Biomnis, French leader in specialised medical pathology.
-
2008
Technology
Creation of the onco-haematology department, dedicated to the pathologies of malignant haemopathies and solid tumours.
-
2008
Technology
Development of the first therapeutic markers, notably KRAS for colorectal cancer and HER2 for breast cancer.
-
2013
Technology
Biomnis offers new oncology markers: HE4 and Roma score for early diagnosis of ovarian cancer, Septin 9 and [-2] proPSA & Phi index respectively for non-invasive screening of colon and prostate cancers.
-
2013
Technology
Development of NGS technique (New Generation Sequencing) enabling the sequencing of hundreds of thousands of DNA fragments for the diagnosis of genetic diseases.
-
2014
Technology
Biomnis develops an innovative, specialised new test for women via its new screening marker for pre-eclampsia in the 1st trimester of pregnancy.
-
2014
Technology
Application of NGS method to the Non-Invasive Prenatal Testing of trisomies 13, 18 and 21
-
2014
Technology
Mass Spectrometry as chosen method for immunosuppressant drug testing and the therapeutic monitoring of transplanted patients. With over 400 specimens tested per day, Biomnis laboratories is placed n° 1 in Europe for the testing of these immunosuppressants by LC-MS-MS.
-
2015
Technology
Performance of new companion diagnostic tests for personalised medicine in oncology, enabling chemotherapy dose adjustment (5-FU).